Capital Increase / Dilution2026-06-15

HYUNDAI BIOSCIENCE to issue CBs for funding

HMC

현대바이오

048410

+0.05

Signal Score

52CNeutral
Score52 / 100

Historical Avg Return (5d)

+0.38%

Data Coverage

100%n=2330

Risk-adjusted indicator based on 2330 historical DART filings. For informational purposes only — not investment advice.

Financial Impact

NEUTRAL

Key Numbers

  • • Early redemption yield: 4.0% per annum (compounded quarterly)
  • • Call option interest rate: 4.0% per annum (compounded annually)
  • • First early redemption date: December 23, 2027 (106.1520% redemption rate)
  • • First call option exercise date: June 23, 2027 (104.0604% exercise amount)

AI Analysis Summary

HYUNDAI BIOSCIENCE CO., LTD. has decided to issue convertible bonds. The bonds feature an early redemption option for bondholders starting December 23, 2027, with a yield of 4.0% per annum. The company also retains a call option, allowing it to repurchase bonds from June 23, 2027, at an annual compounded rate of 4.0%. Specifics on the total issuance amount, conversion price, and purpose of funds are not disclosed in this report, limiting a full assessment of dilution and financial impact. The lack of these key figures makes a definitive financial impact assessment difficult, but the structured nature of the CB with both put and call options suggests a balanced approach to financing.

Track Korean Market Signals — Free

Sign up free to access live disclosures, AI analysis, and event filters.

Public Beta · No credit card required

This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.

AI-processed analysis. Based on: 주요사항보고서(전환사채권발행결정). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.